Genetic susceptibility to psoriasis and psoriatic arthritis: implications for therapy

Authors

  • H.L. Hébert,

    1. Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester Academic Health Science Centre, Manchester, Stopford Building, Manchester, M13 9PT, U.K.
    Search for more papers by this author
  • F.R. Ali,

    1. Dermatological Sciences, Salford Royal Hospital, University of Manchester, Manchester Academic Health Science Centre, Manchester M6 8HD, U.K.
    Search for more papers by this author
  • J. Bowes,

    1. Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester Academic Health Science Centre, Manchester, Stopford Building, Manchester, M13 9PT, U.K.
    Search for more papers by this author
  • C.E.M. Griffiths,

    1. Dermatological Sciences, Salford Royal Hospital, University of Manchester, Manchester Academic Health Science Centre, Manchester M6 8HD, U.K.
    Search for more papers by this author
  • A. Barton,

    1. Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester Academic Health Science Centre, Manchester, Stopford Building, Manchester, M13 9PT, U.K.
    Search for more papers by this author
  • R.B. Warren

    1. Dermatological Sciences, Salford Royal Hospital, University of Manchester, Manchester Academic Health Science Centre, Manchester M6 8HD, U.K.
    Search for more papers by this author

  • Funding sources
    H.L.H. is funded by a PhD studentship from Abbott; J.B. and A.B. are funded by Arthritis Research U.K. (grant ref. 17552).

  • Conflicts of interest
    R.B.W. has acted as a consultant and/or speaker for Abbott, Janssen Cilag, Leo Pharma, Pfizer and Schering Plough (now MSD). C.E.M.G. has acted as consultant for and/or received research grants from Abbott, Biogen-IDEC, Biotest, Centocor, Incyte, Janssen-Cilag, Leo Pharma, MSD and Pfizer. Other authors, none declared.

Richard Warren.
E-mail: richard.warren@manchester.ac.uk

Summary

The era of genome-wide association studies has revolutionized the search for genetic susceptibility loci in complex genetic conditions such as psoriasis. There are currently 16 loci with confirmed evidence for association with psoriasis susceptibility but there is the potential for more to be discovered as the genetic heritability of the disease has not yet been fully explained. Many of the associated loci overlap with those for psoriatic arthritis. In contrast to psoriasis susceptibility, few studies have been performed to identify predictors of drug response in psoriasis. As large-scale collaborations and registries for psoriasis and psoriatic arthritis are established, it is likely that a genome-wide approach may be used as a more effective method of searching for genetic predictors of treatment response. However, candidate gene studies will still have a role; for example, it is likely that some disease susceptibility genes will also be markers of treatment response, based on evidence from other diseases. This review summarizes recent advances in investigating the role genetics plays in psoriasis susceptibility and contrasts these to advances made in psoriatic arthritis. Further, it describes the genetics of treatment response in the two diseases and indicates how susceptibility loci could be used to identify drug response in the future.

Ancillary